{"commentary":{"count":3,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":2,"podcast":1},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":false},"name":"RASolve 301","nct_id":"NCT06881784","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=rasolve-301-nct06881784. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":"RASolve 301","arms":[{"description":"study drug","label":"daraxonrasib","type":"EXPERIMENTAL"},{"description":"Patients randomized to the comparator control arm will receive docetaxel as the standard of care therapy.","label":"docetaxel","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2030-12-01","type":"ESTIMATED"},"conditions":["NSCLC (Non-small Cell Lung Cancer)","Non-Small Cell Lung Cancer","NSCLC","NSCLC (Non-small Cell Lung Carcinoma)","NSCLC (Advanced Non-small Cell Lung Cancer)"],"enrollment":{"count":590,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"daraxonrasib","type":"DRUG"},{"name":"docetaxel","type":"DRUG"}],"last_update":"2026-09-29","lead_sponsor":"Revolution Medicines, Inc.","official_title":"RASolve 301: Phase 3 Multicenter, Open Label, Randomized Study of RMC-6236 Versus Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic RAS[MUT] NSCLC","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2027-12-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression free survival (PFS) per Blinded Independent Central Review (BICR) in the RAS G12X-C population (i.e RAS G12X excluding G12C)","timeFrame":"Up to approximately 4 years"},{"measure":"Overall survival (OS) in the RAS G12X-C population","timeFrame":"Up to approximately 4 years"}],"references":[],"start_date":{"date":"2025-05-06","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)","url":"https://clinicaltrials.gov/study/NCT06881784"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/rasolve-301-nct06881784"}